<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_MIT_CRISPR skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:MIT/CRISPR</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="navdiv-wrapper"><DIV class="navdiv"><UL><LI><A href="https://2017.igem.org/Team:MIT/Team">ABOUT US</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/Team">Team</A><A href="https://2017.igem.org/Team:MIT/Attributions">Attributions</A></DIV></LI><LI><A href="https://2017.igem.org/Team:MIT/AS">BACKGROUND</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/AS">Alternative Splicing</A><A href="https://2017.igem.org/Team:MIT/CRISPR">CRISPR</A><A href="https://2017.igem.org/Team:MIT/RBPs">RNA Binding Proteins</A><A href="https://2017.igem.org/Team:MIT/REST">REST</A></DIV></LI><LI><A href="https://2017.igem.org/Team:MIT/project">PROJECT</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/GuidesandASOs">Guides and ASOs</A><A href="https://2017.igem.org/Team:MIT/mk-FF4">mKate-FF4</A><A href="https://2017.igem.org/Team:MIT/2mk-HBG">2 Exon mKate HBG</A><A href="https://2017.igem.org/Team:MIT/3mk-HBG">3 Exon mKate HBG</A><A href="https://2017.igem.org/Team:MIT/3mk-DF">3 Exon Dual Fluorescence</A></DIV></LI><LI><A href="https://2017.igem.org/Team:MIT/notebook">LAB WORK</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/parts">Parts/Improved Parts</A><A href="https://2017.igem.org/Team:MIT/protocols">Protocols</A><A href="https://2017.igem.org/Team:MIT/notebook">Notebook</A><A href="https://2017.igem.org/Team:MIT/Future-Work">Future Work</A></DIV></LI><LI><A href="https://2017.igem.org/Team:MIT/Model">MODELLING</A></LI><LI><A href="#">HUMAN PRACTICES</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/HP/Gold_Integrated">Integrated HP</A><A href="https://2017.igem.org/Team:MIT/Engagement">Public Engagement</A><A href="https://2017.igem.org/Team:MIT/Collaborations">Collaborations</A><A href="https://2017.igem.org/Team:MIT/InterLab">InterLab</A></DIV></LI><LI><A href="https://2017.igem.org/Team:MIT/award">AWARDS</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/HP/Silver">HP Silver</A><A href="https://2017.igem.org/Team:MIT/HP/Gold_Integrated">HP Gold</A><A href="https://2017.igem.org/Team:MIT/Engagement">Education &amp; Public Engagement</A><A href="https://2017.igem.org/Team:MIT/Model">Model</A><A href="https://2017.igem.org/Team:MIT/Part_Collection">Parts Collection</A></DIV></LI></UL></DIV></DIV><H1 style="color:#ff0000; text-align: center; font-size: 40px; line-height: 40px;">CRISPR - dCas13a</H1><H2 style="color:#ffffff; background-color:#ff0000; -moz-border-radius: 15px; -webkit-border-radius: 15px; padding:15px; text-align: center"><I> What is CRISPR?</I></H2><P><CENTER><I>Diagram of CRISPR Pathway</I></CENTER></P><P><B>CRISPR</B> is an acronym for Clustered Regularly Interspaced Short Palindromic Repeats, which refers to a crucial structure of the immune system of various microorganisms. When a bacterial cell is infected by a recurrent virus, the CRISPR immune system can detect the virus and destroy it before it harms the cell. It accomplishes this by using <B>CRISPR-associated proteins</B> (or <B>Cas proteins</B>), which insert short viral DNA segments called <B>spacers</B> between the short palindromic repeats. The short palindromic repeats and spacers are then constitutively transcribed and processed into short segments called <B>CRISPR RNAs</B> (or <B>crRNAs</B>). The crRNAs bind to <B>trans-activating CRISPR RNA</B> (or <B>tracrRNA</B>)* and a Cas protein, such as Cas-9. This RNA-protein complex then seeks out and cuts the viral sequences that are complementary to the crRNA; thus, destroys the invading virus.[1]</P><P>The CRISPR system’s ability to do targeted cutting of nucleotide sequences has proven to be revolutionary for genetic engineering. By utilizing the CRISPR system to target sequences of interest, scientists have been able to do selective knockdown or mutagenesis in nearly every organism the system has been tested. Labs around the whole have developed numerous tools using CRISPR systems that range from diagnosing and treating genetic diseases to regulating gene expression in-vivo. [1] However, until very recently, all known CRISPR systems targeted DNA sequences. It was reported in 2016, that a new Cas protein called Cas13a is RNA targeting, opening a whole new realm of possibilities. [2]</P><P>*In later improvements, the crRNA and tracrRNA sequences were combined into one RNA sequence called the <B>guide RNA</B> (or <B>gRNA</B>).[3]</P></DIV><H2 style="color:#ffffff; background-color:#ff0000; -moz-border-radius: 15px; -webkit-border-radius: 15px; padding:15px; text-align: center"><I> What is CRISPR-dCas13a?</I></H2><P><B>Cas13a</B> is a new Cas protein that, unlike previously characterized DNA-targeting Cas proteins such as Cas-9, has demonstrated RNA-guided RNase activity. Originally discovered in <I>Leptrotrichia shahii</I>, Cas13a provides interference against RNA phage. Biochemical characterization has shown that Cas13a cleave ssRNA targets by using catalytic residues in its two HEPN domains. In deactivating these catalytic residues by mutagenesis, the result is <B>dCas13a</B>, which is able to target and bind to RNA, but unable to cleave RNA. This ability of dCas13a to find an arbitrary binding sequence, makes dCas13a effectively a programmable RNA-binding protein. We want to harness this power of dCas13a to bind to splice sites of interest, thereby occluding the spliceosome from cutting at those sites. [2] 
</P><H3>References</H3><P>[1] Lander, Eric S. “The Heroes of CRISPR.” Cell, vol. 164, no. 1-2, 2016, pp. 18–28., doi:10.1016/j.cell.2015.12.041. </P><P>[2] Abudayyeh, Omar O. et al. “C2c2 Is a Single-Component Programmable RNA-Guided RNA-Targeting CRISPR Effector.” Science (New York, N.Y.) 353.6299 (2016): aaf5573. PMC. Web. 1 Nov. 2017. </P><P> [3]Reis, Alex et al. &quot;CRISPR/Cas9 and Targeted Genome Editing: A New Era in Molecular Biology.&quot; NEB expressions Issue I (2014)</P></DIV></DIV></DIV></DIV></BODY></HTML>